decisionhealth Newsletters, Answer Books - 2006 Issue 7 (July)
Medicare_Benefit_Policy_Manual / Chapter_15 / 50.4.5
Subscribe or sign in to view the full article.
Article Overview
This Medicare coverage policy article addresses how unlabeled uses of anti-cancer drugs and biologicals are evaluated for medically accepted indications. It is relevant to billing and coding professionals, oncology practices, compliance teams, and clinicians who need to understand the policy framework, compendia-based review sources, and the role of peer reviewed literature in coverage determinations.
Why This Topic Matters
The article matters because it describes the policy basis Medicare uses to assess coverage for off-label anti-cancer drug use, including the accepted evidence sources and review process that can affect claim outcomes and documentation needs.
Article Sections
-
50.4.5 - Unlabeled Use for Anti-Cancer Drugs
Introduces the policy framework for evaluating unlabeled anti-cancer drug use in medically accepted regimens and related treatment contexts.
-
Compendia and Medical Literature Sources
Summarizes the compendia and peer reviewed literature sources referenced for determining whether a use may be considered medically accepted.
-
Evidence Review and Coverage Determination
Describes the general factors used to assess supportive clinical evidence and the circumstances under which coverage is not supported.
What You Will Learn
- How Medicare evaluates unlabeled uses of anti-cancer drugs and biologicals
- Which reference sources are used to assess medically accepted indications
- What general types of clinical evidence are considered in coverage review
- How off-label anti-cancer drug use is treated when it is not supported by accepted sources
Who Should Read This
- Medical coders
- Billing staff
- Compliance professionals
- Oncology practices
- Physicians and clinical staff
- Revenue cycle teams
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com